Historically, when Avidity Biosciences traded independently under the NASDAQ ticker symbol RNA, its stock price experienced the severe cyclical volatility typical of clinical-stage biopharmaceutical companies. Temporary downward drops or sharp sell-offs were frequently triggered by broader macroeconomic pressures, rising interest rates pushing capital away from speculative biotech equities, or routine clinical trial delays and adverse patient safety readouts that spooked institutional investors. However, it is crucial to note that this narrative completely reversed in late 2025 when the Swiss pharmaceutical giant Novartis announced a massive twelve-billion-dollar acquisition of Avidity, purchasing the stock for seventy-two dollars per share in cash. This definitive merger agreement caused the stock to surge massively, delivering a massive premium to long-term shareholders before the enterprise was ultimately absorbed and delisted from public exchanges.